The long-acting muscarinic antagonist ( LAMA ) umeclidinium ( UMEC ) and the combination of UMEC with the long-acting 2-agonist ( LABA ) vilanterol ( UMEC/VI ) are approved maintenance treatments for chronic obstructive pulmonary disease ( COPD ) in the US and EU .